Namenda and Glaucoma - a phase IV clinical study of FDA data

Summary:

Glaucoma is reported as a side effect among people who take Namenda (memantine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Proair Hfa, and have Asthma.

The phase IV clinical study analyzes which people have Glaucoma when taking Namenda. It is created by eHealthMe based on reports of 13,521 people who have side effects when taking Namenda from the FDA, and is updated regularly.

What is Namenda?

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia. eHealthMe is studying from 14,283 Namenda users. Check the latest studies of Namenda.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,235 drugs and 1,653 conditions by eHealthMe. Check the latest studies of Glaucoma.

On Jul, 09, 2026

13,521 people reported to have side effects when taking Namenda.
Among them, 34 people (0.25%) have Glaucoma.

Among these 34 people:

How long have people been on Namenda when they have Glaucoma? *

What is the gender of people who have Glaucoma when taking Namenda? *

female: 82.35 %
male: 17.65 %

What is the age of people who have Glaucoma when taking Namenda? *

What are other drugs people take besides Namenda? *

What are other side effects people have besides Glaucoma? *

Blindness: 17 people, 50.00%
Hypoacusis (loss of hearing): 16 people, 47.06%
Nasopharyngitis (inflammation of the nasopharynx): 16 people, 47.06%
Neuropathy Peripheral (surface nerve damage): 16 people, 47.06%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 16 people, 47.06%
Lower Respiratory Tract Infection: 16 people, 47.06%
Laryngeal Nerve Damage: 16 people, 47.06%
Body Height Decreased: 16 people, 47.06%
Rhinorrhea (watery mucus discharge from the nose): 16 people, 47.06%
Hoarseness Or Changing Voice: 16 people, 47.06%

What are the existing conditions these people have? *

Polymyalgia Rheumatica (pain in many muscles): 16 people, 47.06%
Asthma: 16 people, 47.06%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 11 people, 32.35%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 6 people, 17.65%
Heart Rate Irregular: 5 people, 14.71%
Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 5.88%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.88%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 5.88%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 5.88%
Angiopathy (generic term for a disease of the blood vessels): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Namenda and have Glaucoma?

- Check whether Glaucoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Namenda:

Namenda (14,283 reports)

Glaucoma treatments and more:

Glaucoma (61,926 reports)

Browse all side effects of Namenda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glaucoma:

Glaucoma (1,235 drugs)

Browse all the conditions that are associated with Glaucoma:

Glaucoma (1,653 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on memantine hydrochloride (the active ingredients of Namenda) and Namenda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.